BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7:1213-1227. [PMID: 26513491 DOI: 10.2217/imt.15.87] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 2017;8:8910-20. [PMID: 27852042 DOI: 10.18632/oncotarget.13315] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 26.7] [Reference Citation Analysis]
2 Umetsu SE, Brown I, Langner C, Lauwers GY. Autoimmune enteropathies. Virchows Arch. 2018;472:55-66. [PMID: 29022145 DOI: 10.1007/s00428-017-2243-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
3 Chong A, Kashani A, Ansstas M, Jamil L, Guindi M. Seronegative autoimmune enteropathy with duodenal sparing and colonic clues in an adult female. Clin J Gastroenterol 2021;14:546-50. [PMID: 33630282 DOI: 10.1007/s12328-020-01336-9] [Reference Citation Analysis]
4 Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Int J Cancer. 2017;141:1018-1028. [PMID: 28263392 DOI: 10.1002/ijc.30678] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 17.5] [Reference Citation Analysis]
5 Wei W, Luo Z. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. Medicine (Baltimore). 2017;96:e8931. [PMID: 29310385 DOI: 10.1097/md.0000000000008931] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology. 2019;19:587-594. [PMID: 31076344 DOI: 10.1016/j.pan.2019.04.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
7 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA;  National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-1768. [PMID: 29442540 DOI: 10.1200/jco.2017.77.6385] [Cited by in Crossref: 1268] [Cited by in F6Publishing: 535] [Article Influence: 422.7] [Reference Citation Analysis]
8 Abdel-Rahman O, Eltobgy M, Oweira H, Giryes A, Tekbas A, Decker M. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy 2017;9:1175-83. [PMID: 29067884 DOI: 10.2217/imt-2017-0108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
9 Fazio N, Abdel-Rahman O. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now? Curr Treat Options Oncol 2021;22:19. [PMID: 33559013 DOI: 10.1007/s11864-021-00817-4] [Reference Citation Analysis]
10 Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222-234. [PMID: 29512649 DOI: 10.1038/nrgastro.2018.14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
11 Witges K, Shafer LA, Zarychanski R, Abou-Setta AM, Rabbani R, Dingwall O, Bernstein CN. Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. Drug Saf 2020;43:1255-66. [PMID: 32749630 DOI: 10.1007/s40264-020-00979-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer 2019;7:354. [PMID: 31856918 DOI: 10.1186/s40425-019-0813-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 35.0] [Reference Citation Analysis]
13 Ferguson PM, Long GV, Scolyer RA, Thompson JF. Impact of genomics on the surgical management of melanoma. Br J Surg 2018;105:e31-47. [PMID: 29341162 DOI: 10.1002/bjs.10751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Abdel-rahman O, Helbling D, Schmidt J, Petrausch U, Giryes A, Mehrabi A, Schöb O, Mannhart M, Zidan A, Oweira H. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. Clinical Oncology 2016;28:e127-38. [DOI: 10.1016/j.clon.2016.06.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
15 Cutroneo PM, Isgrò V, Ientile V, Santarpia M, Ferlazzo G, Fontana A, Carrega P, Matarangolo E, Barnaba S, Spina E, Trifirò G. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. Br J Clin Pharmacol 2021;87:527-41. [PMID: 32495965 DOI: 10.1111/bcp.14413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Cañete F, Mañosa M, Lobatón T, Mesonero F, Rodríguez-Lago I, Cabré E, Cabriada JL, López-Sanromán A, Domènech E. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. Int J Colorectal Dis 2019;34:861-5. [PMID: 30826963 DOI: 10.1007/s00384-019-03268-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Doyle E, Crew J, Mostafid H, Tuthill M, Cerundolo V, Gerristen W, Protheroe A. Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. BJU Int 2019;123:947-58. [PMID: 30548196 DOI: 10.1111/bju.14643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Ali MA, Matboli M, Tarek M, Reda M, Kamal KM, Nouh M, Ashry AM, El-Bab AF, Mesalam HA, Shafei AE, Abdel-Rahman O. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy? Immunotherapy 2017;9:99-108. [PMID: 28000527 DOI: 10.2217/imt-2016-0111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
19 Rahouma M, Karim NA, Baudo M, Yahia M, Kamel M, Eldessouki I, Abouarab A, Saad I, Elmously A, Gray KD, Ghaly G, Gaber O, Kamal M, A Hassan A, Rahouma M, D'Ascenzo F, Morris J, Mohamed A, Girardi L, Gaudino M. Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Immunotherapy 2019;11:725-35. [PMID: 31088241 DOI: 10.2217/imt-2018-0118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
20 Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, Kondo M, Kanamori A, Iijima M, Goda K, Nozawa Y, Ishida K, Irisawa A. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel) 2021;9:418. [PMID: 33916353 DOI: 10.3390/healthcare9040418] [Reference Citation Analysis]
21 Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. [PMID: 29540345 DOI: 10.1136/bmj.k793] [Cited by in Crossref: 194] [Cited by in F6Publishing: 171] [Article Influence: 64.7] [Reference Citation Analysis]
22 Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. In: Balch CM, Atkins MB, Garbe C, Gershenwald JE, Halpern AC, Kirkwood JM, Mcarthur GA, Thompson JF, Sober AJ, editors. Cutaneous Melanoma. Cham: Springer International Publishing; 2020. pp. 1187-214. [DOI: 10.1007/978-3-030-05070-2_60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
24 Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018;4:1-7. [PMID: 29756118 DOI: 10.1016/j.cdtm.2017.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shao J, Wang C, Ren P, Jiang Y, Tian P, Li W. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep 2020;40:BSR20192347. [PMID: 32315071 DOI: 10.1042/BSR20192347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
26 Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67. [DOI: 10.1136/gutjnl-2018-316948] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 24.7] [Reference Citation Analysis]
27 Eltobgy M, Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schöb O, Giryes A, Decker M, Abdel-rahman O. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Review of Neurotherapeutics 2017;17:725-36. [DOI: 10.1080/14737175.2017.1336088] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
28 Abdel-rahman O, Helbling D, Schmidt J, Petrausch U, Giryes A, Mehrabi A, Schöb O, Mannhart M, Oweira H. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Clinical Oncology 2017;29:218-30. [DOI: 10.1016/j.clon.2016.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
29 Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy 2016;8:665-74. [PMID: 27140415 DOI: 10.2217/imt-2015-0020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
30 Wang Y, Kong D, Wang C, Chen J, Li J, Liu Z, Li X, Wang Z, Yao G, Wang X. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. Technol Cancer Res Treat 2020;19:1533033820967454. [PMID: 33084525 DOI: 10.1177/1533033820967454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schöb O, Giryes A. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther 2017;17:387-94. [PMID: 28277102 DOI: 10.1080/14737140.2017.1296765] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 19.0] [Reference Citation Analysis]
32 Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol. 2016;101:75-85. [PMID: 26969107 DOI: 10.1016/j.critrevonc.2016.03.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
33 Stucci S, Palmirotta R, Passarelli A, Silvestris E, Argentiero A, Lanotte L, Acquafredda S, Todisco A, Silvestris F. Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management. Oncol Lett 2017;14:5671-80. [PMID: 29113194 DOI: 10.3892/ol.2017.6919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
34 Zhu J, Wu J, Li G, Li J, Lin Y, He Z, Su C, Zhao W, Wu Q, Chen Z, Qiu K. Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opin Drug Saf 2017;16:423-8. [PMID: 28276859 DOI: 10.1080/14740338.2017.1297420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
35 Rofi E, Del Re M, Arrigoni E, Rizzo M, Fontanelli L, Crucitta S, Gianfilippo G, Restante G, Fogli S, Porta C, Danesi R, Schmidinger M. Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology 2020;154:102891. [DOI: 10.1016/j.critrevonc.2020.102891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
37 Cui PF, Ma JX, Wang FX, Zhang J, Tao HT, Hu Y. Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag 2017;13:1259-71. [PMID: 29026313 DOI: 10.2147/TCRM.S143939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
38 Abdel-Rahman O. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Immunotherapy 2016;8:1081-9. [PMID: 27485080 DOI: 10.2217/imt-2016-0025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
39 Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology. 2017;70:558-567. [PMID: 28000302 DOI: 10.1111/his.13118] [Cited by in Crossref: 110] [Cited by in F6Publishing: 77] [Article Influence: 22.0] [Reference Citation Analysis]
40 de Andrea CE, Perez-Gracia JL, Castanon E, Ponz-Sarvise M, Echeveste JI, Melero I, Sanmamed MF, Rodriguez-Ruiz ME. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. Oncoimmunology 2020;9:1760676. [PMID: 32934876 DOI: 10.1080/2162402X.2020.1760676] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, Daikos GL, Gogas H. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. Cancer Invest. 2017;35:443-455. [PMID: 28548891 DOI: 10.1080/07357907.2017.1324032] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
42 Damato A, De Marco L, Serra S, Larocca M, Arias AG, Rondini E, Pinto C. Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report. Front Oncol 2021;11:670415. [PMID: 34221986 DOI: 10.3389/fonc.2021.670415] [Reference Citation Analysis]
43 Abdel-rahman O, Oweira H, Giryes A. Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. Expert Review of Anticancer Therapy 2018;18:1231-9. [DOI: 10.1080/14737140.2018.1528146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019;7:184. [PMID: 31307547 DOI: 10.1186/s40425-019-0662-5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 115] [Article Influence: 74.5] [Reference Citation Analysis]
45 Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 2016;10:183-93. [PMID: 26944362 DOI: 10.1177/1753465816636557] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 15.8] [Reference Citation Analysis]
46 Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 2018;96:91-104. [PMID: 29698933 DOI: 10.1016/j.ejca.2018.03.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 19.7] [Reference Citation Analysis]
47 Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 2020;8:E61. [PMID: 32188078 DOI: 10.3390/biomedicines8030061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
48 Chang CY, Park H, Malone DC, Wang CY, Wilson DL, Yeh YM, Van Boemmel-Wegmann S, Lo-Ciganic WH. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2020;3:e201611. [PMID: 32211869 DOI: 10.1001/jamanetworkopen.2020.1611] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
49 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
50 Rofi E, Del Re M, Arrigoni E, Rizzo M, Fontanelli L, Crucitta S, Gianfilippo G, Restante G, Fogli S, Porta C, Danesi R, Schmidinger M. Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology 2019;144:102812. [DOI: 10.1016/j.critrevonc.2019.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]